CorMedix Inc. (NASDAQ:CRMD) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET

Company Participants

Daniel Ferry - LifeSci Advisors, LLC

Erin Mistry - Senior Vice President and Head, Payer Strategy, Government Affairs and Trade

Joseph Todisco - Chief Executive Officer

Matt David - Executive Vice President & Chief Financial Officer

Phoebe Mounts - Executive Vice President & General Counsel

Conference Call Participants

Rohit Bhasin - Needham & Co.

Operator

Greetings and welcome to the CorMedix Inc. Second Quarter 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Dan Ferry from Life Science Advisors. Please go ahead.

Daniel Ferry

Good morning. And welcome to the CorMedix second quarter 2022 earnings conference call. Leading the call today is Joe Todisco, Chief Executive Officer of CorMedix. And he is joined by Dr. Matt David, Executive Vice President and CFO; Dr. Phoebe Mounts, EVP, General Counsel; and Head of Technical Operations, Erin Mistry, SVP of Commercial.

Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties and include but are not limited to, any of the following: any statements other than statements of historical fact regarding management's expectations, beliefs, goals and plans about the company's prospects, including its clinical development program, manufacturing activities and marketing approval, for DefenCath in the U.S. and other product candidates; future financial position; future revenues and projected costs; and potential market acceptance of DefenCath, Neutrolin and other product candidates. More specifically, forward-looking statements include any statements about our clinical development plans and the timing, cost, progress, results, estimates and interpretations thereof, projections as to the company's future capital raising and spending and cash position; expectations as to the timing and nature of anticipated regulatory actions; possible product licensing, business development or other transactions; any commercial plans and expectations, market projections for our product candidates; and expectations as to manufacturing and product component costs. Actual results may differ materially from these projections or estimates due to a variety of important factors, including but not limited to, uncertainties related to clinical development, regulatory approvals and commercialization. These risks are described in greater detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in these forward-looking statements and investors should not place undue reliance on these statements. Please note that CorMedix does not intend to update these forward-looking statements, except as required by law.